Vivax Malaria Human Infection Studies in Thailand
ConditionPlasmodium Vivax Infection
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-55
SponsorUniversity of Oxford
About this trial
This study is a human challenge study to assess the feasibility and safety of controlled human malaria infection (via P. vivax sporozites) in healthy volunteers, and to develop a bank of P. vivax-infected blood for use in future controlled human P. vivax malaria infection studies. Additional objectives are to obtain data on host immune response to P. vivax infection and pre-treatment gametocytaemia.
This study is funded by the UK Wellcome Trust. The grant reference number are Oxford/MORU: 212336/Z/18/Z and 212336/Z/18/A, and Mahidol University: 212336/A/18/Z and 212336/A/18/A.
Eligibility criteria
Qualifiers
Healthy adult aged 20 to 55 years with weight more than 50 kg.
Blood group O.
Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).
CYP2D6 alleles consistent with normal metaboliser status
Disqualifiers
History of clinical malaria.
Positive malaria PCR OR malaria film OR malaria serology (recent exposure)
History of severe allergy to mosquito bite
Presence of any medical condition (either physical or psychological) which in the judgment of the investigator would place the participant at undue risk or interfere with the results of the study (e.g. serious underlying cardiac, renal, hepatic or neurological disease; severe malnutrition; congenital defects or febrile condition)
Trial design
Treatments tested in this trial
- Mosquito bites
Treatment groups
6 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Oxford
Lead sponsor
Mahidol University
Collaborator
Source ClinicalTrials.gov